Comparison of Discontinuation and Continuation of Tamsulosin in Benign Prostatic Hyperplasia Patients with Combination Therapy of Tamsulosin and Dutasteride

Hong Sang Moon¹, Joo Yong Lee¹, Kyoung Taek Lim¹, Seung Wook Lee¹, Joong Shik Lee², Yong Tae Kim¹, Hong Yong Choi¹

From Department of Urology, College of Medicine, ¹Hanyang University and ²Cheil General Hospital, Kwandong University

Hypothesis / aims of study

- This study was conducted to compare symptoms of patients with discontinuation and continuation of tamsulosin who had been diagnosed of benign prostatic hyperplasia (BPH) and undergone combination therapy of tamsulosin and dutasteride.

Study design, materials and methods

- This study included 108 men with BPH who visited our clinic from April, 2008 and October, 2010.
- All patients had not been given tamsulosin or dutasteride to treat BPH before the study commenced.
- All subjects were assessed by using International Prostate Symptom Score (IPSS).
- After 48 weeks, randomization was performed and patients were given same combination drugs (group 1) or only dutasteride 0.5 mg (group 2).

Results

- IPSS between two groups at first visit, 48 weeks and 72 weeks was 14.7 vs. 15.8 (p=0.322), 12.1 vs. 12.8 (p=0.582) and 10.9 vs. 11.9 (p=0.897) (Fig. 2).

Concluding message

In patients with moderate IPSS before the treatment, there were not statistically significant differences on IPSS between tamsulosin discontinuation group and combination therapy group after 72 weeks combination therapy period.